Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression

Clinical Infectious Diseases

Volumn 55, Issue 10, 2012, Pages 1417-1425

  Thiébaut, Rodolphe ^a,b,c   Charpentier, Charlotte ^d   Damond, Florence ^d   Taieb, Audrey ^a   Antoine, Romain ^d   Capeau, Jacqueline ^a,e   Chêne, Geneviève ^a,b,c   Collin, Gilles ^d   Matheron, Sophie ^f   Descamps, Diane ^d   Brun Vézinet, Françoise ^d  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; INTERLEUKIN 6; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNOLOGICAL PARAMETERS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; VIROLOGY; VIRUS DETECTION;

ADULT; ANTIGENS, CD14; ANTIGENS, CD4; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-2; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84868027906     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis708     Document Type: Article

References (40)

1. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90.
2. Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116-21.
3. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325-30.
4. Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010; 51:833-43.
5. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52:780-7.
6. Rowland-Jones SL, Whittle HC. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nature Immunol 2007; 8:329-31.
7. Thiébaut R, Matheron S, Taieb A, Brun-Vezinet F, Chêne G, Autran B. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. AIDS 2010; 25:865-7.
8. Matheron S, Pueyo S, Damond F, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003; 17:2593-601.
9. Martinez Steele E, Awasana AA, Corrah T, et al. Is HIV-2-induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317-24.
10. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine cohort, 2000-2004. HIV Med 2007; 8:547-54.
11. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-48.
12. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-55.
13. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
14. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-83.
15. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95.
16. Kamat A, Ancuta P, Blumberg RS, Gabuzda D. Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation. PLoS One 2010; 5:e15533.
17. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201:1796-805.
18. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
19. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-46.
20. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011; 25:1385-94.
21. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-94.
22. Eastburn A, Scherzer R, Zolopa AR, et al. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 2011; 6:e26320.
23. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
24. Leligdowicz A, Feldmann J, Jaye A, et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis 2010; 201:114-22.
25. Michel P, Balde AT, Roussilhon C, Aribot G, Sarthou JL, Gougeon ML. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis 2000; 181:64-75.
26. Gourlay AJ, van Tienen C, Dave SS, et al. Clinical predictors cannot replace biological predictors in HIV-2 infection in a community setting in West Africa. Int J Infect Dis 2012; 16:e337-43.
27. Yeni P. Prise en charge médicale des personnes infectées par le VIH [Medical management of HIV-infected persons]. Paris: La documentation française, 2010:417.
28. Drylewicz J, Matheron S, Lazaro E, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-68.
29. Damond F, Descamps D, Farfara I, et al. Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR. J Clin Microbiol 2001; 39:4264-8.
30. Damond F, Collin G, Descamps D, et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 2005; 43:4234-6.
31. Vivot A, Chêne G, Thiébaut R, et al. Peak HIV-2 RNA better predicts clinical progression in HIV-2+ adults than baseline or current values or copy-years. In: Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 2012.
32. Thiébaut R, Jacqmin-Gadda H, Chêne G, Leport C, Commenges D. Bivariate linear mixed models using SAS proc MIXED. Comput Methods Programs Biomed 2002; 69:249-56.
33. Brenchley JM, Schacker TW, Ruff LE, et al. CD4(+) T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-59.
34. Nowroozalizadeh S, Mansson F, da Silva Z, et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis 2010; 201:1150-4.
35. El Sadr WM, Lundgren JD, Neaton JD, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
36. Sheikh V, Krishnan S, Richterman A, et al. D-dimer levels are elevated in HIV-infected LTNP despite normal C-reactive protein and sCD14 levels. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2011.
37. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202:723-33.
38. Merlini E, Bai F, Bellistri GM, Tincati C, d'Arminio Monforte A, Marchetti G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 2011; 6:e18580.
39. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-30.
40. Nyamweya S, De Silva T, Van Tienen C. A study of 3 biomarkers of immune activation and disease progression: a comparison between HIV-1 and HIV-2 infections. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2011.